Vitamin D as an Important Steroid Hormone in Breast Cancer

Česká verzia

Authors: R. Obermannová ¹; R. Demlová ^2,3; K. Drábová ⁴; K. Melichárková ⁴; K. Greplová ³; M. Mrkvicová ³; L. Zdražilová Dubská ³; R. Vyzula ^1,3; D. Valík ³
Authors place of work: Klinika komplexní onkologické péče, Masarykův onkologický ústav, Brno ¹; Farmakologický ústav, LF MU, Brno ²; Regionální centrum aplikované molekulární onkologie, Masarykův onkologický ústav, Brno ³; Klinika dětské onkologie LF MU a FN Brno ⁴
Published in the journal: Klin Onkol 2014; 27(Supplementum): 143-149

Summary

Vitamin D is the third steroid hormone playing important biological roles in the development of breast cancer. Decreased plasma levels of its 25- hydroxyderivative, 25‑OHD, display robust associations with higher incidence of breast cancer and shorter overall survival. Although no consensus exists, most authors agree that optimal plasma levels shall be within 75– 150 nmol/ l whereas levels higher than 375 nmol/ l can be potentially toxic with higher risk of hypercalcemia. To date, no data are available on the optimal levels of vitamin D related to the risk of breast cancer development, its phenotype features and the course of the disease. Published studies mostly describe associations among higher levels of 25‑OHD and lower biologically aggressiveness of the tumor. The polymorphism of VDR gene coding for the steroid receptor for vitamin Dmay be associated with higher disease incidence and also be of negative prognostic significance in breast cancer. This review presents an overall summary of the current knowledge and publications on vitamin D and breast cancer.

Key words:
vitamin D – 25- hydroxyvitamin D – vitamin D receptor – breast cancer

This work was supported by the European Regional Development Fund and the State Budget of the Czech Republic (RECAMO, CZ.1.05/2.1.00/03.0101) and by MH CZ – DRO (MMCI, 00209805) and BBMRI_CZ (LM2010004).

The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.

The Editorial Board declares that the manuscript met the ICMJE “uniform requirements” for biomedical papers.

Submitted:
29. 1. 2014

Accepted:
5. 5. 2014

Zdroje

1. Svod.cz [internetová stránka]. Dušek L, Mužík J, Kubásek M et al. Epidemiologie zhoubných nádorů v České republice [online]. Masarykova univerzita, Česká republika; c2005, [citováno 5. února 2014]. Dostupný z: http:/ / www.svod.cz.

2. Fisher B, Costantino JP, Wickerham DL et al. Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project P‑ 1 study. J Natl Cancer Inst 1998; 90(18): 1371– 1388.

3. Vogel VG, Costantino JP, Wickerham DL et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: The NSABP study of tamoxifen and raloxifene (STAR) P‑ 2 trial. JAMA 2006; 295(23): 2727– 2741.

4. Goss PE, Ingle JN, Alés‑ Martínez JE et al. Exemestane for breast‑ cancer prevention in postmenopausal women. N Engl J Med 2011; 364(25): 2381– 2391. doi: 10.1056/ NEJMoa1103507.

5. Crew KD. Vitamin D: are we ready to supplement for breast cancer prevention and treatment? ISRN Oncol 2013; 2013: 483687. doi: 10.1155/ 2013/ 483687.

6. Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357(3): 266– 281.

7. Krishnan AV, Swami S, Peng L et al. Tissue selective regulation of aromatase expression by calcitriol: implications for breast cancer therapy. Endocrinology 2010; 151(1): 32– 42.

8. James SY, Mackay AG, Binderup L et al. Effects of a new synthetic vitamin D analogue, EB1089, on the oestrogen‑ responsive growth of human breast cancer cells. J Endocrinol 1994; 141(3): 555– 563.

9. Stoica A, Saceda M, Fakhro A et al. Regulation of estrogen receptor‑alpha gene expression by 1,25- dihydroxyvitamin D in MCF‑ 7 cells. J Cell Biochem 1999; 75(4): 640– 651.

10. Garland FC, Garland CF, Gorham ED et al. Geographic variation in breast cancer mortality in the United States: a hypothesis involving exposure to solar radiation. Prev Med 1990; 19(6): 614– 622.

11. Apperley FL. The relation of solar radiation to cancer mortality in North America. Cancer Res 1941; 1: 191– 195.

12. Studzinski GP, Moore DC. Sunlight – can it prevent as well as cause cancer? Cancer Res 1995; 55(18): 4014– 4022.

13. Gorham ED, Garland FC, Garland CF. Sunlight and breast cancer incidence in the USSR. Int J Epidemiol 1990; 19(4): 820– 824.

14. Blot WJ, Fraumeni JF Jr, Stone BJ. Geographic patterns of breast cancer in the United States. J Natl Cancer Inst 1977; 59(5): 1407– 1411.

15. Chen W, Clements M, Rahman B et al. Relationship between cancer mortality/ incidence and ambient ultraviolet B irradiance in China. Cancer Causes Control 2010; 21(10): 1701– 1709. doi: 10.1007/ s10552- 010- 9599- 1.

16. Ross C, Taylor CL, Yaktine AL, Del Valle HB (eds). Dietary reference intakes for calcium and vitamin D [monograph on the Internet]. Washington: National Academies Press (US); 2011 [cited 2014 February]. Available from: http:/ / www.ncbi.nlm.nih.gov/ books/ NBK56070/ .

17. Eitenmiller RR, Ye L, Landen WO Jr (eds). Vitamin analysis for the health and food sciences. 2nd ed. Boca Raton, FL, USA: CRC Press 2008.

18. Shin MH, Holmes MD, Hankinson SE et al. Intake of dairy products, calcium and vitamin D and risk of breast cancer. J Natl Cancer Inst 2002; 94(17): 1301– 1311.

19. Lin J, Manson JE, Lee IM et al. Intakes of calcium and vitamin D and breast cancer risk in women. Arch Intern Med 2007; 167(10): 1050– 1059.

20. McCullough ML, Rodriguez C, Diver WR et al. Dairy, calcium and vitamin d intake and postmenopausal breast cancer risk in the cancer prevention study II nutrition cohort. Cancer Epidemiol Biomarkers Prev 2005; 14(12): 2898– 2904.

21. Robien K, Cutler GJ, Lazovich D. Vitamin D intake and breast cancer risk in postmenopausal women: the Iowa women’s health study. Cancer Causes Control 2007; 18(7): 775– 782.

22. Sperati F, Vici P, Maugeri‑ Saccà M et al. Vitamin D supplementation and breast cancer prevention: a systematic review and meta‑analysis of randomized clinical trials. PLoS One 2013; 8(7): e69269. doi: 10.1371/ journal.pone.0069269.

23. Mohr SB, Gorham E, Alcaraz JE et al. Serum 25- hydroxyvitamin D and prevention of breast cancer: pooled analysis. Anticancer Res 2011; 31(9): 2939– 2948.

24. Fedirko V, Torres‑ Mejía G, Ortega‑ Olvera C et al. Serum 25- hydroxyvitamin D and risk of breast cancer: results of a large population‑based case‑ control study in Mexican women. Cancer Causes Control 2012; 23(7): 1149– 1162. doi: 10.1007/ s10552- 012- 9984- z.

25. Yin L, Grandi N, Raum E et al. Meta‑analysis: serum vitamin D and breast cancer risk. Eur J Cancer 2010; 46(12): 2196– 2205. doi: 10.1016/ j.ejca.2010.03.037.

26. Drábová K, Bienertová‑ Vašků J, Lokaj P et al. Vitamin D – jeho fyziologie, patofyziologie a význam v etiopatogenezi nádorových onemocnění. Čas Lék Čes 2013; 152(1): 20– 30.

27. Blackmore KM, Lesosky M, Barnett H et al. Vitamin D from dietary intake and sunlight exposure and the risk of hormone‑ receptoe‑ defined breast cancer. Am J Epidemiol 2008; 168(8): 915– 924. doi: 10.1093/ aje/ kwn198.

28. Neuhouser ML, Sorensen B, Hollis BW et al. Vitamin insufficiency in a multiethnic cohort of brest cancer survivors. Am J Clin Nutr 2008; 88(1): 133– 139.

29. Anzano MA, Smith JM, Uskokovic MR et al. 1‑alpha,25- dihydroxy‑ 16- ene‑ 23-yne‑ 26,27- hexafluorocholecalciferol, a new delanoid (vitamin D analog) for prevention of brest cancer in the rat. Cancer Res 1994; 54(7): 1653– 1656.

30. Deeb K, Trump DL, Johnson CS. Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nature Rev Cancer 2007; 7(9): 684– 700.

31. Bijlsma MF, Spek CA, Zivkovic D et al. Repression of smoothened by patched‑ dependent (pro‑)vitaminD3 secretion. PLoS Biol 2006; 4(8): e232.

32. Tang JY, Xiao TZ, Oda Y et al. Vitamin D3 inhibits hedgehog signaling and proliferation in murine Basal cell carcinomas. Cancer Prev Res (Phila) 2011; 4(5): 744– 751.

33. Goodwin PJ, Ennis M, Pritchard KI et al. Vitamin D deficiency is common at breast cancer diagnosis and is associated with significantly higher risk of distant recurrence and death in a prospective cohort study of T1- 3, N0- 1, M0 breast cancer. J Clin Oncol 2008; 26 (Suppl): 9.

34. Crew KD, Gammon MD, Steck SE et al. Association between plasma 25- hydroxyvitamin D and breast cancer risk. Cancer Prev Res (Phila) 2009; 2(6): 598– 604. doi: 10.1158/ 1940- 6207.CAPR‑ 08- 0138.

35. Vieth R, Chan PC, MacFarlane GD. Efficacy and safety of vitamin D3 intake exceeding the lowest observed adverse effect level. Am J Clin Nutr 2001; 73(2): 288– 294.

36. Hathcock JN, Shao A, Vieth R et al. Risk assessment for vitamin D. Am J Clin Nutr 2007; 85(1): 6– 18.

37. Khan QJ, Reddy PS, Kimler BF et al. Effect of vitamin D supplementation on serum 25- hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer. Breast Cancer Res Treat 2010; 119(11): 111– 118. doi: 10.1007/ s10549- 009- 0495- x.

38. Amir E, Simmons CE, Freedman OC et al. A phase 2 trial exploring the effects of high‑dose (10,000 IU/ day) vitamin D3 in breast cancer patients with bone metastases. Cancer 2010; 116(2): 284– 291. doi: 10.1002/ cncr.24749.

39. Abbas S, Linseisen J, Slanger T et al. Serum 25- hydroxyvitamin D and risk of post‑menopausal breast cancer‑ results of a large case‑ control study. Carcinogenesis 2008; 29(1): 93– 99.

40. Nielsen TO, Hsu FD, Jensen K et al. Immunohistochemical and clinical characterization of the basal‑like subtype of invasive breast carcinoma. Clin Cancer Res 2004; 10(16): 5367– 5374.

41. Rainville CH, Khan Y, Tisman G. Triple negative breast cancer patients presenting with low serum vitamin D levels: a case series. Cases J 2009; 2: 8390. doi: 10.4076/ 1757- 1626- 2- 8390.

42. Carey LA, Perou CM, Livasy CA et al. Race, breast cancer subtypes, and survival in the Carolina breast cancer study. JAMA 2006; 295(1): 2492– 2502.

43. Laporta E, Welsh J. Modeling vitamin D actions in triple negative/ basal‑like breast cancer. J Steroid Biochem Mol Biol. In press 2013. doi: 10.1016/ j.jsbmb.2013.10.022.

44. Welsh J, Wietzke JA, Zinser GM et al. Vitamin D‑ 3 receptor as target for brest cancer prevention. J Nutr 2003; 133 (Suppl 7): 2425S–2433S.

45. Köstner K, Denzer N, Müller CS et al. The relevance of vitamin D receptor (VDR) gene polymorphisms for cancer: a review of the literature. Anticancer Res 2009; 29(9): 3511– 3536.

46. McKay JD, McCullough ML, Ziegler RG et al. Vitamin Dreceptor polymorphisms and breast cancer risk: results from the National cancer institute breast and prostate cancer cohort consortium. Cancer Epidemiol Biomarkers Prev 2009; 18(1): 297– 305. doi: 10.1158/ 1055- 9965.EPI‑ 08- 0539.

47. Sinotte M, Rousseau F, Ayotte P et al. Vitamin D receptor polymorphisms (FokI, BsmI) and breast cancer risk: association replication in two case‑ control studies within French Canadian population. Endocr Relat Cancer 2008; 15(4): 975– 983. doi: 10.1677/ ERC‑ 08- 0056.

48. Wang H, Wang W, Yang D et al. TaqI polymorphism of VDR gene contributes to breast cancer risk. Tumour Biol 2014; 35(1): 93– 102. doi: 10.1007/ s13277-013- 1011- 9.

49. Autier P, Gandini S. Vitamin D supplementation and total mortality: a meta‑analysis of randomized controlled trials. Arch Intern Med 2007; 167(16): 1730– 1737.

50. Chlebowski RT, Johnson KC, Kooperberg C et al. Calcium plus vitamin D supplementation and the risk of breast cancer. J Natl Cancer Inst 2008; 100(22): 1581– 1591. doi: 10.1093/ jnci/ djn360.

51. Wactawski‑ Wende J, Morley Kotchen J, Anderson GL et al. Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Eng J Med 2006; 354(7): 684– 696.